112 related articles for article (PubMed ID: 15704291)
1. Oleic acid suppresses overexpression of ERBB2 oncogene.
Nelson R
Lancet Oncol; 2005 Feb; 6(2):69. PubMed ID: 15704291
[No Abstract] [Full Text] [Related]
2. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
Menendez JA; Vellon L; Colomer R; Lupu R
Ann Oncol; 2005 Mar; 16(3):359-71. PubMed ID: 15642702
[TBL] [Abstract][Full Text] [Related]
3. Mediterranean diet, olive oil and cancer.
Colomer R; Menéndez JA
Clin Transl Oncol; 2006 Jan; 8(1):15-21. PubMed ID: 16632435
[TBL] [Abstract][Full Text] [Related]
4. Natural medicine: a 'new frontier' in oncology?
Marchetti P
Ann Oncol; 2005 Mar; 16(3):339-40. PubMed ID: 15722460
[No Abstract] [Full Text] [Related]
5. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
Menendez JA; Vazquez-Martin A; Colomer R; Brunet J; Carrasco-Pancorbo A; Garcia-Villalba R; Fernandez-Gutierrez A; Segura-Carretero A
BMC Cancer; 2007 May; 7():80. PubMed ID: 17490486
[TBL] [Abstract][Full Text] [Related]
6. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells.
Menendez JA; Papadimitropoulou A; Vellon L; Lupu R
Eur J Cancer; 2006 Oct; 42(15):2425-32. PubMed ID: 16406575
[TBL] [Abstract][Full Text] [Related]
7. [ERBB2/HER2: from molecular to clinical oncology].
Khanson KP; Imianitov EN
Vopr Onkol; 2002; 48(2):137-45. PubMed ID: 12227060
[No Abstract] [Full Text] [Related]
8. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
9. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
10. Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?
Arteaga CL
Clin Cancer Res; 2007 Feb; 13(4):1071-3. PubMed ID: 17317812
[No Abstract] [Full Text] [Related]
11. Expression status of the autophagy-regulatory gene ATG6/BECN1 in ERBB2-positive breast carcinomas: bypassing ERBB2-induced oncogenic senescence to regulate the efficacy of ERBB2-targeted therapies.
Vazquez-Martin A; Cufí S; Oliveras-Ferraros C; Martin-Castillo B; Del Barco S; López-Bonet E; Menendez JA
Genes Chromosomes Cancer; 2011 Apr; 50(4):284-90. PubMed ID: 21319263
[No Abstract] [Full Text] [Related]
12. Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9).
Menendez JA; Lupu R
Curr Pharm Biotechnol; 2006 Dec; 7(6):495-502. PubMed ID: 17168666
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapies in the Treatment of Breast Cancer. Proceedings of a meeting. Kailua-Kona, Hawaii, July 19-23, 2000.
Semin Oncol; 2001 Oct; 28(5 Suppl 16):1-153; quiz 154-65. PubMed ID: 11760720
[No Abstract] [Full Text] [Related]
15. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?
Arteaga CL
J Clin Oncol; 2006 Aug; 24(23):3722-5. PubMed ID: 16847283
[No Abstract] [Full Text] [Related]
16. Trial watch: ERBB2 dimerization inhibitor meets end point in breast cancer trial.
Nat Rev Drug Discov; 2011 Aug; 10(9):648. PubMed ID: 21878970
[No Abstract] [Full Text] [Related]
17. [Breast cancer--known receptors, new pathways?].
Bürger H
Verh Dtsch Ges Pathol; 2006; 90():124-7. PubMed ID: 17867588
[TBL] [Abstract][Full Text] [Related]
18. Intraductal trastuzumab treatment may be effective in the management of ductal carcinoma in situ of the breast with HER-2 overexpression.
Altundag K; Tezcan ME; Ozen M; Karaahmet F; Bulut N
Med Hypotheses; 2007; 68(1):235. PubMed ID: 16905272
[No Abstract] [Full Text] [Related]
19. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
Cavalloni G; Sarotto I; Pignochino Y; Gammaitoni L; Migliardi G; Sgro L; Piacibello W; Risio M; Aglietta M; Leone F
Anticancer Drugs; 2008 Aug; 19(7):689-96. PubMed ID: 18594210
[TBL] [Abstract][Full Text] [Related]
20. The distinctive nature of HER2-positive breast cancers.
Burstein HJ
N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
[No Abstract] [Full Text] [Related]
[Next] [New Search]